drugset / Trial / NCT02065765

International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer

NCT02065765 ↗

Expanded access Approved for marketing Eli Lilly and Company

Summary

The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the compassionate use program.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Ramucirumab Monoclonal antibody — Intravenous